DLBCL ABC subtype presents with recurrent oncogenic mutations activating both the B-cell receptor (BCR) and MYD88 pathways for driving the NF-κB pathway and favoring cell survival [17]. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.